FY2025 EPS Estimates for Journey Medical Lowered by Analyst

Journey Medical Corporation (NASDAQ:DERM) – Equities researchers at B. Riley dropped their FY2025 earnings per share (EPS) estimates for shares of Journey Medical in a research report issued to clients and investors on Monday, November 3rd. B. Riley analyst M. Mamtani now forecasts that the company will post earnings of ($0.38) per share for the year, down from their previous forecast of ($0.29). The consensus estimate for Journey Medical’s current full-year earnings is ($1.02) per share. B. Riley also issued estimates for Journey Medical’s FY2026 earnings at $0.43 EPS and FY2027 earnings at $1.49 EPS.

Several other analysts have also weighed in on DERM. HC Wainwright assumed coverage on Journey Medical in a research note on Monday, August 25th. They issued a “buy” rating and a $13.00 price objective on the stock. Lake Street Capital raised their price target on shares of Journey Medical from $9.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, August 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Journey Medical in a research report on Wednesday, October 8th. Finally, Zacks Research upgraded shares of Journey Medical from a “strong sell” rating to a “hold” rating in a research report on Monday, October 13th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Journey Medical has an average rating of “Hold” and a consensus target price of $12.17.

Journey Medical Trading Up 5.6%

Shares of DERM opened at $9.00 on Wednesday. Journey Medical has a 52-week low of $3.54 and a 52-week high of $9.01. The business’s fifty day moving average is $7.40 and its 200-day moving average is $7.24. The company has a debt-to-equity ratio of 1.11, a quick ratio of 0.95 and a current ratio of 1.27. The firm has a market cap of $236.79 million, a price-to-earnings ratio of -23.68 and a beta of 0.80.

Journey Medical (NASDAQ:DERM) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.09). Journey Medical had a negative return on equity of 48.69% and a negative net margin of 15.49%.The firm had revenue of $15.01 million for the quarter, compared to analyst estimates of $14.93 million.

Institutional Investors Weigh In On Journey Medical

Hedge funds have recently added to or reduced their stakes in the business. Police & Firemen s Retirement System of New Jersey acquired a new position in Journey Medical in the 2nd quarter valued at approximately $29,000. Bank of America Corp DE grew its stake in shares of Journey Medical by 4,707.0% in the second quarter. Bank of America Corp DE now owns 4,134 shares of the company’s stock worth $30,000 after purchasing an additional 4,048 shares during the last quarter. Raymond James Financial Inc. bought a new position in Journey Medical during the 2nd quarter worth $36,000. JPMorgan Chase & Co. bought a new stake in Journey Medical in the second quarter valued at approximately $41,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Journey Medical during the 2nd quarter worth about $48,000. 7.25% of the stock is currently owned by institutional investors and hedge funds.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.